| Methods | Randomised, double‐blind trial conducted at Neurology clinic of Ahvaz Golestan Hospital, Iran 2 treatment arms: OXC or PHT |
| Participants | Participants > 65 years with partial and secondary generalised epilepsy |
| Interventions | Monotherapy with PHT or OXC for 6 months Maximum dose: PHT = 600 mg/d, OXC = 600 mg/d |
| Outcomes | Seizure symptoms Adverse events |
| Notes | Trial registered as IRCT201202068943N1 on the Iranian Registry of Clinical Trials. We have attempted to contact the trial authors for more information |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.